Clinical Trial: A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA(R) (Levonorgestrel and Ethinyl Estradiol) Transdermal System

U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07739589) titled 'A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA(R) (Levonorgestrel and Ethinyl Estradiol) Transdermal System' on July 28.

Brief Summary: The objective of this open-label study was to assess residual EE and LNG content on used Twirla(R) TDSs, packaging, and the skin surface at the application site after 7 full days of wear and the estimate EE and LNG loaded on control TDSs using valid analytical methods.

Study Start Date: Oct. 25, 2021

Study Type: INTERVENTIONAL

Condition: Residual Drug Amount of EE and LNG

Intervention: DRUG: Twirla(R) (Levonorgestrel/Ethinyl...